Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Biotech Stock Pops After FDA Approves Mylan-Partnered Lung Disease Drug.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): GATLIN, ALLISON
- Source:
Investors Business Daily. 11/9/2018, pN.PAG-N.PAG. 1p.
- Subject Terms:
- Additional Information
- Subject Terms:
- Abstract:
The article offers information on the increase in stock price of Theravance Biopharma after its chronic lung disease treatment with Mylan received approval from the U.S. Food and Drug Administration on November 9, 2018. Topics discussed include approval of the drug Yupelri as a treatment for chronic obstructive pulmonary disease; lung disease treatment to relax the muscles around the airways; and becoming the first long-acting bronchodilator.
No Comments.